• Lipocine posted a net loss of USD 3.7 million, or USD 0.52 per diluted share, for first quarter ended March 31, 2026, widening from a net loss of USD 1.9 million, or USD 0.35 per diluted share, a year earlier.
• Royalty revenue rose to USD 119,000 from USD 94,000.
• Research and development expense climbed to USD 2.8 million from USD 1.1 million, mainly on higher costs tied to the LPCN 1154 clinical study.
• Unrestricted cash, cash equivalents, and marketable investment securities increased to USD 24.7 million as of March 31, 2026 from USD 14.9 million at Dec. 31, 2025.
• Phase 3 trial of LPCN 1154 in postpartum depression missed its primary endpoint, though the drug was well tolerated; Lipocine applied for breakthrough therapy and fast track designations, awaiting FDA feedback.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipocine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-021638), on May 07, 2026, and is solely responsible for the information contained therein.